Disclaimer
NovusValue.com is not a broker or dealer, and none of its content represents recommendations to buy or sell securities. Information provided on the site is not intended as investment advice. Novus Value is not liable for damages from using its content, including investment losses. Past performance does not indicate future results, and information is not guaranteed for accuracy or completeness.1-Line Summary
180 Life Sciences Corp. innovates biotechnological solutions for chronic pain and fibrosis with 3 key product platforms.
180 Life Sciences Corp. is a clinical-stage biotechnology company, headquartered in Palo Alto, California, dedicated to developing therapeutics for chronic pain, inflammation, and fibrosis. The company's approach primarily focuses on unmet medical needs and utilizes three main product development platforms: Anti-TNF, SCAs, and α7 nAChR, which are aimed at addressing conditions such as Dupuytren's Contracture, frozen shoulder, and post-operative cognitive decline. Through innovative research and combination therapy, they aim to advance treatment options that are currently non-existent or limited within the market.
The company leverages significant expertise from leading scientists associated with prestigious institutions such as Oxford and Stanford. Their business model heavily relies on the advancement through various clinical trial stages, with a focus on regulatory approvals in the UK, EU, and US markets. Currently, their lead product candidate has successfully completed Phase 2 trials, and they are preparing plans for future trials to expand their therapeutic offerings, demonstrating a strategic alignment with meeting pressing healthcare demands and potential commercialization in diverse healthcare markets.
Automaticly searches the internet using AI for the current investing thesis for 180 Life Sciences Corp. (ATNF) and summarizes it. Only available for paid users.